Murine infection by vesicular stomatitis virus: initial characterization of the H-2d system.
BALB/c mice and congenic H-2Ld-deficient BALB/c-H-2dm2 (dm2) mice were experimentally infected intranasally with isolates of vesicular stomatitis virus (VSV). The survival of infected hosts, viral replication in lungs and brains, and histopathologic in the two mouse strains were compared. In both strains of mice, mortality occurred during the period 7 to 10 days postinfection. However, dm2 mice were relatively resistant to lethal infections. Viral replication occurred at low levels in the lungs of both strains and did not evoke significant pathologic changes. In contrast, viral replication in the brains was much greater; in the BALB/c strain, this was accompanied by more frequent and more severe pathologic changes. In general, mice surviving at day 10 had effectively cleared virus from central nervous system but not respiratory sites. Evidence is presented that viral replication occurs first in the nasal cavity and is transmitted both to the lungs and to the olfactory bulb where focal cytopathology occurs. Virus enters the ventricles, causing encephalitis; necrosis occurs around the ventricles and in the lumbosacral region of the spinal cord. Necrotic lesions were accompanied by mononuclear infiltration. Mice immunized with virus of the same serotype or with a vaccinia virus hybrid encoding the VSV glycoprotein were protected from lethal infection; in contrast, mice immunized with heterotypic virus were susceptible to challenge.
Forger
J M
JM
Division of Infectious Diseases, Children's Hospital, Boston, Massachusetts.
Bronson
R T
RT
Huang
A S
AS
Reiss
C S
CS
D000818:Animals; D001921:Brain / Q000276:immunology / Q000473:pathology; D006183:H-2 Antigens / Q000276:immunology*; D008168:Lung / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000473:pathology; D013116:Spinal Cord / Q000473:pathology; D013997:Time Factors; D014721:Vesicular stomatitis Indiana virus / Q000472:pathogenicity*; D014765:Viral Vaccines / Q000627:therapeutic use; D014777:Virus Diseases / Q000276:immunology / Q000382:microbiology* / Q000473:pathology / Q000517:prevention & control
D006183:H-2 Antigens; D014765:Viral Vaccines